{"nctId":"NCT04387617","briefTitle":"A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones","startDateStruct":{"date":"2021-02-15","type":"ACTUAL"},"conditions":["Urinary Stone"],"count":90,"armGroups":[{"label":"CBD Oil Group","type":"EXPERIMENTAL","interventionNames":["Drug: Cannabidiol"]},{"label":"Control Group","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Cannabidiol","otherNames":["Epidiolex"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who are diagnosed with kidney or ureteral stones confirmed on imaging (CT of the abdomen and pelvis) and who elect for definitive treatment via ureteroscopy at two sites within a tertiary care institution.\n* Age 18-75 years of age.\n* Patients of either gender.\n* Patients of all ethnic backgrounds.\n* Capable of giving informed consent.\n* Capable and willing to fulfill the requirements of the study.\n\nExclusion Criteria:\n\n* History of chronic pain.\n* Chronic use of opioid or other pain medication (\\> 12 weeks).\n* Known allergy to CBD oil or other cannabinoids.\n* Known or suspected pregnancy.\n* Inability to give informed consent or unable to meet requirements of the study for any reason.\n* Bilateral ureteroscopy.\n* Current marijuana, cannabidiol (CBD), or dronabinol use.\n* Liver disease/cirrhosis.\n* Current treatment of seizures with clobazam, valproate, or other antiepileptic medications.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Pain Intensity Score","description":"Patient self-reported maximum pain intensity score measured by the Visual Analogue Scale (VAS) rated from 0-10, where 0 was no pain and 10 was the worst pain imaginable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"2.4"},{"groupId":"OG001","value":"3.2","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Postoperative Rescue Narcotic Use","description":"The number of subjects who required rescue narcotic use post ureteroscopy","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Urinary Symptoms Score","description":"Patient self-reported urinary symptoms measured by the Ureteric Stent Symptoms Questionnaire (USSQ) urinary symptoms section. Following insertion of the stents, subjects were asked to answer 11 questions regarding their urinary symptoms. 9 questions used a score of 1 to 5, where 1 was never and 5 was all of the time. 1 question used a score of 1 to 4, where 1 was do not see any blood and 4 was urine is heavily blood stained. 1 question used a score of 1 to 7, where 1 was delighted and 7 was terrible. Total sum of all 11 questions for a total score ranging from 11 - 56, lower scores reflected fewer symptoms and higher satisfaction where higher scores reflected more symptoms and less satisfaction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":"5.5"},{"groupId":"OG001","value":"33","spread":"6.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":"5.8"},{"groupId":"OG001","value":"27","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"The Number of Subjects With Adverse Events","description":"The count of subjects who experienced adverse events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":45},"commonTop":["Tiredness","Constipation","Drowsiness","Poor sleep","Poor Appetite"]}}}